Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
| 7.35 | |
| 7.49 | |
| - | |
| 7.55 | |
| 7.2101 | |
| 3.21-10.6899 | |
| 113 M | |
| 15 221 K | |
| 6 129 K | |
| -0.35 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of the bad stuff out of the way ...
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer a...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
